Palmitoylethanolamide (PEA) has a strong safety profile based on the clinical evidence available. Across more than 20 clinical trials involving nearly 2,000 patients, no serious side effects have been reported. The rare adverse events that do show up, like mild stomach discomfort or brief palpitations, affect a very small number of people and tend to resolve quickly on their own.
Why PEA Is Well Tolerated
One of the main reasons PEA causes so few problems is that your body already makes it. PEA is produced naturally in your cells from fatty building blocks in cell membranes, and it gets broken down by two dedicated enzymes into palmitic acid and ethanolamine, both of which are ordinary substances your body handles every day. It also shows up in common foods like eggs and milk. When you take PEA as a supplement, you’re essentially topping up something your body already recognizes and knows how to process.
This natural origin also means PEA doesn’t linger in the body for long. Those same two enzymes break it down relatively quickly, which limits the window for unwanted effects but also means the compound’s action is short-lived.
Side Effects Reported in Trials
In the majority of clinical trials, the side effects column for PEA simply reads “none reported.” When adverse events do appear, they are mild and infrequent. In one trial of 30 patients taking 600 mg daily, one person experienced drowsiness and another had palpitations lasting two to three hours. In a separate trial of 20 patients taking 800 mg daily (combined with another supplement), three people reported mild, temporary gastrointestinal symptoms.
A review published in the British Journal of Clinical Pharmacology concluded that for treatment periods up to about seven weeks, the data rule out serious adverse reactions occurring in more than 1 in 200 people. For treatment lasting longer than 60 days, fewer patients have been studied, so the data can only rule out serious reactions occurring in more than 1 in 100 people. That gap is a limitation of the existing research rather than a red flag.
Doses Used in Clinical Studies
Clinical trials have used oral doses ranging from 300 mg to 1,200 mg per day, given either once or twice daily. Most studies cluster around 600 mg per day. Interestingly, researchers haven’t found a clear relationship between higher doses and stronger effects within that range, which suggests that more isn’t necessarily better.
Animal toxicity studies push the safety margin much further. In a prenatal developmental toxicity study conducted under international guidelines, pregnant rats received up to 1,000 mg per kilogram of body weight daily with no adverse effects on the mothers, embryos, or fetuses. Converted to a human equivalent dose, that translates to more than 9.7 grams per day, roughly 10 to 30 times the doses used in human supplements. No signs of organ damage, hormonal disruption, or developmental harm appeared at any dose level tested.
Drug Interactions
No drug interactions with PEA have been documented. In clinical case series, PEA has been combined with common pain medications including tramadol, pregabalin, gabapentin, and duloxetine without any adverse interactions or added discomfort. Across all published trials, no harmful combinations with other drugs have surfaced. This is likely related to PEA’s nature as a fatty acid compound the body already produces, meaning it doesn’t compete with the liver enzymes responsible for processing most medications.
Safety in Children
A pilot study tested PEA in 70 children (average age about 10) with migraine, giving them 600 mg per day for three months. Only one child developed mild side effects: nausea and a floating sensation. No serious adverse reactions or drug interactions were recorded during the study, and overall adherence was good. The effective dose worked out to roughly 40 mg per kilogram of body weight per day. While this is a single study with a small sample, the tolerability profile was consistent with what’s seen in adults.
Pregnancy and Breastfeeding
The animal data on pregnancy is reassuring. Rats given PEA throughout gestation at doses far exceeding any human supplement showed no maternal toxicity, no increased pregnancy loss, and no fetal abnormalities. However, no clinical trials have tested PEA in pregnant or breastfeeding women. Without human data in these populations, the safety picture during pregnancy and lactation remains incomplete.
What We Still Don’t Know
The biggest gap in PEA’s safety record is long-term data. Most clinical trials have lasted 7 to 12 weeks. A 12-month safety study is currently underway, tracking serious adverse events, blood pressure, heart rate, blood counts, liver function, blood sugar, and cholesterol in people taking PEA for a full year. Until those results are published, the long-term safety profile relies mainly on the absence of concerning signals in shorter studies and on PEA’s status as an endogenous compound.
PEA is sold as a dietary supplement in the United States, where it was filed with the FDA as a new dietary ingredient in 2014. It is not an approved drug, which means supplement manufacturers are responsible for their own quality control. The purity and formulation of PEA products can vary between brands. Micronized or ultra-micronized forms are used in most clinical research because standard PEA powder dissolves poorly in water, limiting how much your body actually absorbs.